Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pierre Fabre
'Still Bad Out There' - Drug Makers In APAC Prepare For Worst Before It Gets Better
Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.
Lilly Migraine Deal Gives AffaMed New Mojo In Changing China: Video Interview
A mega deal with Eli Lilly to exclusively market, promote and distribute Emgality (galcanezumab) in China for migraine prevention offers a critical opportunity for C-Bridge backed AffaMed in an untapped, large market, CFO Vijay Karwal told Scrip in an exclusive video interview on the sidelines of EBD's Asia Bio Partnering Forum.
Scorpion Partners Two Assets With Pierre Fabre To Prioritize Investment In A Third
The oncology start-up signed a co-development and commercialization agreement with the French pharmaceutical company for two next-generation EGFR inhibitors.
China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer
CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.
- Pharmacy Services, PBMs
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Pierre Fabre Medicament S.A.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.